A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy
This study is investigating a new medicine called SHP611 for children diagnosed with Metachromatic Leukodystrophy (MLD). The main goal is to find out if SHP611, when injected directly into the fluid surrounding the brain and spinal cord, can help children keep their ability to walk and move around for a longer time. Researchers will also be observing how this medicine affects a child's movement and speech. Another important aim is to understand how well children tolerate the medicine and if there are any side effects. Children taking part in the study will receive SHP611 for around two years, with the possibility of continuing treatment for longer if the study shows it to be helpful.
Em resumo
Resultados
Resultados deste estudo
Publicado June 2024Os resultados foram publicados para este estudo.
Sobre o que é este estudo?
This study is looking at a new approach to treating Metachromatic Leukodystrophy (MLD) in children. MLD is a rare genetic condition that affects the brain and nervous system, making it difficult for children to move, speak, and learn over time. Currently, there isn't a cure, so researchers are constantly working to find treatments that can help.
The medicine being tested in this study is called SHP611. It's given through an injection directly into the fluid that surrounds the brain and spinal cord, which is known as 'intrathecal' delivery. This method is used because it helps the medicine reach the areas where it's needed most to hopefully slow down the progression of the disease.
The main purpose of this study is to see if SHP611 can help children with MLD keep their ability to move around independently for a longer period. The researchers will also be carefully monitoring other important aspects of a child's health, such as their ability to speak and their overall movement. It's also very important to find out if SHP611 is safe and well-tolerated by children.
Pontos principais
- This study explores a new medicine (SHP611) for children with MLD.
- The medicine is given by injection into the spinal fluid.
- The main goal is to help children keep their ability to move for longer.
- Researchers will also check its effects on speech and safety.
- Participation lasts about two years, with possible extension.
Quem pode ser elegível?
To join this study, children must have a formal diagnosis of Metachromatic Leukodystrophy (MLD). This means tests would have shown specific changes in their blood (low ASA activity) and urine (high sulfatides).
Children need to be within a specific age range, generally between 6 months and 6 years old, depending on their specific MLD symptoms. They must also have certain levels of symptoms. For some, this means having difficulty walking due to MLD by 2 and a half years old. Others might be very young (6 to under 18 months), showing very few symptoms, but having the same MLD gene changes as an older child in their family. Another group might be between 12 and under 18 months old, showing early MLD symptoms, but having previously been able to walk steadily.
Finally, parents or legal guardians must be able to follow the study schedule and must give their written permission for their child to take part.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Does my child have a confirmed MLD diagnosis?
- Is my child between 6 months and 6 years old (age varies by specific MLD symptoms)?
- Does my child meet certain criteria for MLD symptom severity or progression?
- Can I commit to following the study's schedule of appointments and procedures?
- Am I able to give informed consent for my child to participate?
O que envolve a participação?
If your child takes part in this study, they will receive the study medicine, SHP611, for about two years. There might be a chance to continue receiving the medicine for a longer time after this initial period. The medicine will be given by injection directly into the fluid around the brain and spinal cord.
Throughout the study, there will be regular visits to the clinic so that doctors can carefully monitor your child's health, track their movement and speech, and check for any changes or side effects. These assessments help the research team understand how the medicine is working and how your child is responding. You'll be given a detailed schedule of visits and what each visit will involve.
Riscos e benefícios potenciais
Localizações (30)
- Los Angeles Biomedical Research Institute at Harbor-UCLACódigo postal verificadoTorrance, Estados Unidos
- Childrens Hospital ColoradoCódigo postal verificadoAurora, Estados Unidos
- Rare Disease Research, LLCCódigo postal verificadoAtlanta, Estados Unidos
- Ann & Robert H. Lurie Children's Hospital of ChicagoCódigo postal verificadoChicago, Estados Unidos
- University of Iowa Stead Family Children's HospitalCódigo postal verificadoIowa City, Estados Unidos
- Mayo Clinic - PPDSCódigo postal verificadoRochester, Estados Unidos
- Centro Médico Langone da Universidade de Nova YorkCódigo postal verificadoNova Iorque, Estados Unidos
- Cincinnati Children's Hospital Medical CenterCódigo postal verificadoCincinnati, Estados Unidos
- Hospital Infantil da FiladélfiaCódigo postal verificadoFiladélfia, Estados Unidos
- Children's Hospital of PittsburghCódigo postal verificadoPittsburgh, Estados Unidos
- University of UtahCódigo postal verificadoSalt Lake City, United States
- Hospital Universitario Austral - PINApenas cidadeCiudad Autónoma Buenos Aires, Argentina
Perguntas frequentes
What is Metachromatic Leukodystrophy (MLD)?
MLD is a rare genetic disease that affects the brain and nervous system, leading to problems with movement, speech, and other abilities over time.
What is SHP611?
SHP611 is the experimental medicine being tested in this study. It's hoped it can help children with MLD.
How is SHP611 given?
It's given as an injection into the fluid that surrounds the brain and spinal cord, similar to a lumbar puncture.
How long will my child be in the study?
Children will receive the medicine for about two years, and there might be an option for longer treatment.
Is this medicine available to everyone?
No, SHP611 is an investigational medicine, which means it's still being studied and is not yet available outside of clinical trials.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.